FIELD: medicine.
SUBSTANCE: method involves treating hepatitis C virus infection or hepatitis B virus infection by introducing carboxamidine of formula 1 or its pharmaceutically permissible salt at a dose of 0.1-40.0 mg/kg of body mass. Α-interferon is also introduced. Compound of formula 1 is in D-configuration.
EFFECT: enhanced effectiveness of treatment.
7 cl, 5 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MODULATION OF IMMUNE RESPONSE DUE TO RIBAVIRIN | 1999 |
|
RU2211698C2 |
| MONOESTER COMPOUNDS, PHARMACEUTICAL COMPOSITION | 1994 |
|
RU2139884C1 |
| NEW 1-(-D-RIBOFURANOSIL-3-(5-SUBSTITUTED-1,2,4-OXADIAZOLE-3-YL)-1,2,4-TRIAZOLES WITH ANTI-VIRAL PROPERTIES AND METHOD FOR THEIR PRODUCTION | 2016 |
|
RU2629360C1 |
| MODULATION OF EXPRESSION OF CYTOKINES TH1/TH2 BY RIBAVIRIN AND RIBAVIRIN ANALOGS IN ACTIVATED T-LYMPHOCYTES | 1997 |
|
RU2186569C2 |
| 2-AMINO-5,6-DIFLUOR-1-(BETA-D-RIBOFURANOSYL)-BENZIMIDAZOLE, METHOD FOR PRODUCTION AND ANTIVIRAL ACTIVITY IN TERMS OF HERPES SIMPLEX VIRUS TYPE I | 2016 |
|
RU2629670C2 |
| NUCLEOSIDE INHIBITORS OF RNA-POLYMERASE HCV NS5B, METHODS FOR PRODUCTION AND USE THEREOF | 2014 |
|
RU2567854C1 |
| ANTIVIRAL NUCLEOSIDES | 2006 |
|
RU2422454C2 |
| MONOCYCLIC L-NUCLEOSIDES, THEIR ANALOGUES AND USING | 1997 |
|
RU2188828C2 |
| PROMEDICINES OF MODIFIED 2'- AND 3'-NUCLEOSIDES FOR TREATMENT OF FLAVIVIRIDAE INFECTIONS | 2003 |
|
RU2366661C2 |
| MODIFIED 2- AND 3-NUCLEOSIDES AND USE THEREOF TO PRODUCE MEDICINAL AGENT, HAVING HEPATITIS C INHIBITING ACTIVITY | 2003 |
|
RU2437892C2 |
